Last-resort drug offered to brain cancer patients with no options left
NCT ID NCT06404034
First seen Mar 09, 2026 · Last updated Jun 06, 2026 · Updated 13 times
Summary
This program provides an experimental drug called gallium maltolate (GaM) to adults with glioblastoma that has come back or not responded to treatment. It is for patients who have run out of standard therapies. The goal is to see if GaM can help control the disease, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Partners of Nebraska
Lincoln, Nebraska, 68516, United States
-
Northwell Health
New York, New York, 10075, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.